Getting a GLP-1 at a Med Spa: How to Evaluate the Offer

How to tell a medically run GLP-1 program from a product sale in any setting, starting with who actually examines you.

You went in for a facial, or maybe a Botox touch-up, and there it was on the menu: a weight-loss injection, priced by the month, sitting right next to the aesthetic services. Maybe a friend gets hers there and loves it. The offer might be perfectly fine. It might also be a product on a shelf with very little medicine behind it. The hard part is that you cannot tell which one you are looking at from the price or the waiting-room decor. So here is a practical way to evaluate a GLP-1 offer in an aesthetic setting, using the same questions that hold up anywhere.

The setting is not the thing to judge

It is tempting to decide by the sign over the door. A med spa must be cutting corners; a doctor's office must be careful. Reality does not sort that neatly. A GLP-1 like semaglutide or tirzepatide can be prescribed well or poorly in any setting, whether a med spa, a telehealth app, a primary-care office, or a dedicated metabolic clinic. Plenty of med spas run a genuine medical program under a licensed prescriber and a physician medical director, and some meet every standard below. What you are actually evaluating is the care model, not the label. The questions that follow travel with you to any door.

Who writes the prescription, and did anyone evaluate you?

A GLP-1 is a prescription medication. It takes a licensed prescriber, meaning a physician, or a nurse practitioner or physician assistant working within a delegated scope, plus a real practitioner-patient relationship built through a bona fide medical evaluation, sometimes called a good faith exam. That means someone qualified reviews your history, your weight history, your other medications, and your contraindications before anything is prescribed. In states such as Texas, reviewing an intake questionnaire by itself does not meet that bar. Most states also require a med spa to operate under a licensed physician medical director, with written standing orders that govern how any prescribing is delegated.

So ask plainly: who is the prescriber, are they licensed in my state, and will they actually evaluate me before I get a prescription? If the answer is that you fill out a form and pick up an injection, that is a warning sign in any setting. The pattern of a fast, form-only visit is worth learning to spot, and we walk through it in signs of a rushed consult.

Is there a real diagnosis, or just a product?

This is the heart of it. A medically run obesity program starts with a diagnosis and a clinical assessment, not a sale. That usually means looking at BMI and weight-related conditions, your weight history, possible secondary or genetic causes, and the mental-health and life factors that shape eating and weight. It means screening for contraindications, such as a personal or family history of medullary thyroid cancer or MEN 2, a history of pancreatitis, or pregnancy, and ordering baseline labs where they are indicated. A transactional "buy the injection" offer skips most of that, because from a product-sales angle that work is friction.

You do not need to become a clinician to notice the difference. If nobody asked about your health beyond your credit card, the medicine is being sold, not prescribed. What good GLP-1 care looks like describes the fuller version of this.

Titration and side effects: is there a plan?

GLP-1 medicines are not start-and-forget. The dose is meant to be adjusted over time by a qualified clinician, and side effects like nausea need active management. This matters even more with compounded products. The FDA has warned about dosing errors with compounded injectable semaglutide, where patients drawing doses from multi-dose vials, and professionals miscalculating them, led to adverse events including nausea, vomiting, dehydration, and fainting, with some cases serious enough for hospitalization. A setting that hands you a vial with no clear titration plan and nobody managing side effects is not offering supervision. It is offering a product. Ask who adjusts your dose, how, and who takes the call when your stomach rebels in week two.

Continuity: who do you call when something goes wrong?

Aesthetic services are episodic by nature. You come in, you get a treatment, you leave. A GLP-1 is ongoing, and problems do not schedule themselves around business hours. So find out what happens on a Sunday night when you cannot keep water down, or when a symptom worries you. Is there a clinician who knows your case, or only a front desk that reopens Monday? The American Medical Association has adopted policy opposing arrangements that undermine the physician-patient relationship and the continuity of care, and primary-care physicians have publicly raised concerns about fast, product-focused prescribing that arrives with no real follow-up. Continuity is not a luxury feature here. It is part of the medicine.

The compounded product itself

Many aesthetic-setting offers use compounded semaglutide or tirzepatide, so it helps to know what that is. Compounded versions are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before they reach you. The FDA has flagged some compounded products using unapproved salt forms, such as semaglutide sodium or acetate, whose equivalence to the approved ingredient is not established, and has warned about fraudulent products carrying false labels that name pharmacies which do not exist. As of April 30, 2025, the FDA had received roughly 520 adverse-event reports for compounded semaglutide and about 480 for compounded tirzepatide, close to 1,150 combined by late July 2025. The FDA is careful to note that such reports do not prove the drug caused the event and that the figures are likely underreported.

There is also a legal shift worth understanding. The shortages that once allowed widespread compounding have ended. The FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025, and the enforcement discretion that covered compounding pharmacies ended in early 2025. Routinely compounding what amounts to a copy of an available, FDA-approved GLP-1 is generally no longer permitted, aside from narrow patient-specific exceptions. If an offer leans on brand names it does not own, that is its own red flag. The American Med Spa Association warns against marketing compounded products under brand names and points patients toward licensed, reputable pharmacies, and the FDA has sent warning letters to med spas and telehealth companies over marketing it deemed false or misleading. If your source is compounded, it is worth learning how to verify a compounding pharmacy.

The questions to bring with you

You can carry a short list into any consultation:

• Who is the prescriber, and are they licensed in my state?
• Will a clinician actually evaluate my history and screen contraindications before prescribing?
• Am I getting a diagnosis and baseline labs, or just an injection?
• Who adjusts my dose and manages side effects over time?
• If something goes wrong after hours, who do I call?
• Is the product FDA-approved or compounded, and if compounded, which pharmacy prepares it?

None of these are hostile questions. A medically run offering will answer them easily. If you want the longer version of how to weigh one option against another, how to choose a clinic lays it out.

A fair bottom line

There is no blanket verdict here, and it would be unfair to give one. A reputable med spa can meet every standard on this page, and a polished office can fall short of them. What separates good care from a product sale is not the sign out front. It is whether a licensed prescriber truly evaluates you, screens for what could hurt you, orders the right labs, plans your dose, manages side effects, and stays reachable. Judge the offer by that, wherever you find it.

Compounded semaglutide and tirzepatide are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality; results vary by individual. Ozempic and Wegovy are products of Novo Nordisk, and Mounjaro and Zepbound are products of Eli Lilly. New Hope Weight Loss is not affiliated with these companies. This article is educational and is not medical advice; do not start, stop, or change any prescription on your own.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.